Title: An intracerebral hemorrhage care bundle is associated with lower case-fatality

Running head: Acute care bundle in intracerebral hemorrhage

Authors: Adrian R Parry-Jones PhD[1,2], Camilla Sammut-Powell PhD[3], Kyriaki Paroutoglou MRCP[2], Emily Birleson BSc[2], Joshua Rowland MRes[1], Stephanie Lee DipHE[2], Luca Cecchini MRCP[2], Mark Massyn MRCP[2], Richard Emsley PhD[4], Benjamin Bray MD[5], Hiren Patel PhD[2]

[1]Division of Cardiovascular Sciences, School of Medicine, Faculty of Biology, Medicine & Health. The University of Manchester, Manchester Academic Health Science Centre, Oxford Road, Manchester, M13 9PL, UK
[2]Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Stott Lane, Salford, M6 8HD, UK
[3]Greater Manchester Connected Health Cities, Centre for Health Informatics, Faculty of Biology Medicine and Health, University of Manchester, Manchester M13 9PL, UK
[4]Centre for Biostatistics, School of Health Sciences, The University of Manchester, Manchester, M13 9PL, UK
[5]Department of Population Health Sciences, King's College London, SE1 1UL, UK

Corresponding Author:
Dr A.R. Parry-Jones
Clinical Sciences Building
Salford Royal NHS Foundation Trust
Stott Lane
Salford
M6 8HD, UK
E-mail: adrian.parry-jones@manchester.ac.uk
Tel: +44 161 2064458

Key words: intracerebral hemorrhage; blood pressure; neurosurgery; critical care

Abstract:

Objective: Anticoagulation reversal, intensive blood pressure lowering, neurosurgery and access to critical care might all be beneficial in acute intracerebral hemorrhage (ICH). We combined and implemented these as the 'ABC' hyperacute care bundle and sought to determine whether the implementation was associated with lower case fatality.

Methods: The ABC bundle was implemented from 1 June 2015 to 31 May 2016. Key process targets were set and a registry captured consecutive patients. We compared 30-day case fatality before, during and after bundle implementation with multivariable logistic regression and used mediation analysis to determine which care process measures mediated any association. Difference-in-difference analysis compared 30-day case fatality with 32,295 patients with ICH from 214 other hospitals in England and Wales using Sentinel Stroke National Audit Programme data.

Results: 973 ICH patients were admitted in the study period. Compared to before implementation, the adjusted odds of death by 30 days were lower in the implementation period (odds ratio [OR] 0·62; 95% confidence interval [CI] 0·38 to 0·97; p=0·03) and this was sustained after implementation (OR 0·40; 95%CI: 0·24 to 0·61; p<0·0001). Implementation of the bundle was associated with a 10·8 pp (95%CI -17·9 to -3·7; p=0·003) reduction in 30-day case fatality in difference-in-difference analysis. The total effect of the care bundle was mediated by a reduction in do-not-resuscitate orders within 24 h (52·8%) and increased admission to critical care (11·1%).

Interpretation: Implementation of the ABC care bundle was significantly associated with lower 30-day case fatality after ICH.

Introduction:

Intracerebral hemorrhage (ICH) has the worst outcomes of all stroke sub-types, with a case-fatality at one month of 30 to 40% and only 20% regaining independence.[1] Globally, hemorrhagic stroke accounts for 49% of 6·5 million annual stroke deaths and 58% of disability adjusted life years lost to stroke.[2] Despite this substantial health burden, there are few effective treatments and this may lead to pessimism amongst clinicians when managing ICH patients.[3]

Improving the implementation of existing evidence-based and guideline-recommended interventions might lead to improved outcomes. 10 to 20% of acute ICH occurs in patients taking oral anticoagulants and this is associated with a high risk of early hematoma expansion.[4,5] Rapid treatment to normalize coagulation reduces this risk and might improve outcomes.[5,6] Intensive blood pressure (BP) lowering within six hours of onset to a target systolic BP (SBP) of 130 to 140 mmHg was shown to reduce disability and improve quality of life at 90 days in a pre-specified secondary analysis of the INTERACT2 trial, but this intervention can be challenging to implement.[7] Neurosurgery to evacuate the hematoma or treat hydrocephalus might improve outcome but no single randomized controlled trial has been positive and who to operate on and when remains uncertain. An individual patient data meta-analysis of trials of early hematoma evacuation for supratentorial ICH shows patients with larger hematomas (20 to 50 ml) and with reduced consciousness but who are not comatose (Glasgow Coma Scale [GCS] score 9 to 12) might to benefit from hematoma evacuation.[8] Surgery for cerebellar ICH is widely recommended and associated with lower mortality,[9] but has not been tested in a randomized controlled trial.

Whether effective delivery of these interventions together improves survival is unknown. We aimed to evaluate the implementation of a care bundle combining these interventions (The 'ABC' care bundle) on case fatality rates for patients with acute ICH. We considered individual patient randomization to be unethical and not

feasible and so conducted the study in the setting of a quality improvement program at a large Comprehensive Stroke Centre in the United Kingdom. Using data from detailed local and national clinical registries, including data from all stroke centers in England, we sought to use quasi-experimental methods to evaluate the impact of the care bundle on 30-day case fatality in patients with ICH and to determine the contribution of individual bundle components to any overall treatment effects.

Methods:

Intervention:

The Acute Bundle of Care for Intracerebral Hemorrhage (ABC-ICH) project ran from 1 June 2015 to 31 May 2016 at Salford Royal NHS Foundation Trust, a large Comprehensive Stroke Centre and regional Neurosurgical Centre in Greater Manchester, UK. A multidisciplinary team of stroke physicians, neurosurgeons, stroke nurses and managers contributed to the project with support from a local innovation and improvement science center through a program of three 3-day workshops, monthly webinars, improvement coaching and site visits. The ABC-ICH project aim was to reduce 30-day case fatality after acute ICH through consistent and effective delivery of the 'ABC' acute care bundle. The ABC care bundle comprises evidence-based interventions recommended in the American Stroke Association ICH guidelines[10] and the Royal College of Physicians National Clinical Guideline for Stroke,[11] and we set the following process targets:

A. Rapid anticoagulant reversal, with delivery of four-factor prothrombin complex concentrate (PCC) for vitamin-K antagonists and anti-Xa antagonists or idarucizumab for dabigatran within 90 min of arrival.

B. Delivery of intensive blood pressure lowering to an SBP target of 130-140 mmHg for patients arriving within 6 h of onset with an SBP over 150 mmHg. We aimed for a needle-to-target time (NTT; time from the first dose of an intravenous antihypertensive to achieving target SBP) of < 60 min.

C. Adherence to a care pathway prompting immediate neurosurgical referral of all patients with good pre-morbid function (modified Rankin Scale [mRS] score

≤ 2) and any of: GCS < 9; posterior fossa ICH; an obstructed 3rd/4th ventricle; hematoma volume > 30 ml (measured by the ABC/2 method[12]).

Improvements in ABC care bundle delivery were achieved through engagement of senior leaders, training and education including simulations, audit and feedback to clinical teams, and plan-do-study-act (PDSA) cycles to improve care processes. We made changes to improve speed of anticoagulation reversal prior to the period of data collection for the ABC-ICH project, including the use of point-of-care coagulation testing, a supply of PCC in the Emergency Department and a protocol to proceed with treatment without hematology referral.[13] Key changes to optimize intensive blood pressure lowering were the introduction of a standard protocol with a clear treatment escalation policy, the introduction of first-line, nurse-led treatment with intravenous glyceryl trinitrate and the provision of a one-page quick reference sheet. The care pathway was facilitated by engagement with senior clinicians in neurosurgery and critical care.

Measurement:

A clinical registry was established on 1 June 2015, including all consecutive patients with spontaneous ICH admitted to Salford Royal Hospital between 1 June 2013 and 31 May 2017. Patients with traumatic ICH, hemorrhagic transformation of ischemic stroke and primary subdural or subarachnoid hemorrhage were excluded. Baseline characteristics, clinical presentation, acute care processes, clinical observations and diagnostic brain imaging characteristics were extracted from the electronic patient record (EPR) for entry into the registry. We collected whether patients were admitted directly to Salford Royal Hospital, transferred from elsewhere, or had their ICH as an in-patient. Brain scans were reviewed by experienced stroke clinicians to determine ICH location, intraventricular hemorrhage and hematoma volume using the ABC/2 method.[12] We reviewed multiple overlapping databases to ensure complete case ascertainment including clinical coding, neurosurgical referral database and national quality registry data, all of which were established and operational throughout the period of data collection. Time periods were defined as 'before implementation' (1

June 2013 to 31 May 2015), 'implementation' (1 June 2015 to 31 May 2016) and 'after implementation' (1 Jun 2016 to 31 May 2017). Key process data were prospectively entered and regularly reviewed at team meetings from 1 June 2015.

Outcomes and hypotheses:

The primary outcome was 30-day all-cause case fatality. In-hospital and post-discharge deaths were ascertained by data linkage between the hospital EPR and the national statutory register of patient deaths. A survival check was performed for all cases on 5 October 2017, giving a minimum of 5 months follow-up. Secondary outcomes were key process and care measures and included door-to-needle time (DNT) for anticoagulation reversal, needle-to-target time (NTT) for intensive blood pressure lowering, percentage of patients undergoing neurosurgery within 72 h of arrival, percentage of patients with a do-not-resuscitate (DNR) order within 24 h of arrival in hospital, and percentage of patients admitted to critical care (high dependence unit [HDU] or intensive care unit [ICU]) within 72 h of arrival. Our primary hypothesis was that implementation of the acute care bundle would be associated with a significant reduction in 30-day case fatality during the implementation period compared to the period before implementation at our center and contemporary data from the rest of England and Wales. Our secondary hypothesis was that in addition to improving relevant process targets, implementation of the care bundle would lead to enhanced supportive care, as measured by more admissions to higher level care and fewer DNR orders within 24 h of admission.

Statistical analysis: 30-day case fatality for patients admitted to Salford with ICH was compared between time periods using Kaplan-Meier analysis with the logrank test for statistical significance. Process and care measures were compared between time periods using the Kruskal-Wallis test. We fitted multivariable logistic regression models to compare 30-day case fatality between time periods, adjusting for key prognostic factors in ICH. A quasi-experimental analysis used difference-in-

difference analysis to compare the change in 30-day case fatality rates before and after the bundle implementation with data from the national quality registry of stroke (the Sentinel Stroke National Audit Programme; SSNAP). This was done to provide additional control against unmeasured confounders and to control for secular improvements in stroke outcomes unrelated to the intervention. Data from SSNAP included data on patients with ICH admitted to all stroke centers in England and Wales during the study period. Model-based causal mediation analysis[14,15] was performed to determine the average causal mediation effects for the care and process measures that changed as part of the implementation of the care. The proportion mediated is reported for the parts of the care bundle that were significant in improving the 30-day case fatality. The study was approved by the Health Research Authority (Ref: 18/HRA/0384).

Results:

973 patients were captured in the Salford ICH registry during the study period (Figure 1). Because they could not have benefited from the acute care bundle, we excluded all patients where a decision was made restrict care to palliation only within one hour of arrival in hospital (n=66) or who were not under the care of stroke or neurosurgery during their admission (n=44). In addition, patients with missing data were removed (n=3) leaving 353 in the before implementation group, 266 in the implementation group and 241 in the after implementation group. There were no statistically significant differences in baseline clinical and imaging characteristics between the groups before (Table 1) and after (Table 2) excluding palliated patients

or those under other specialties. Compared to the before implementation period, unadjusted 30-day case fatality fell significantly in the implementation period (21·4% vs. 27·8%, p=0·07) and this benefit was sustained in the after implementation period (15·4% vs. 27·7%, p<0·001; Figure 2). After adjusting for pre-morbid mRS, level of consciousness on arrival, infratentorial hemorrhage, age, IVH, ICH volume and anticoagulant use, patients in the intervention period had a lower odds of 30-day case-fatality (OR 0·62, 0·38 to 0·97, p=0·003). This was sustained in the after implementation period (OR 0·40, 0·24 to 0·61, p<0·0001; Table 3). We repeated these analyses for all ICH patients, including patients where a decision was made to restrict care to palliation only within one hour of arrival in hospital and those who were not under the care of stroke or neurosurgery during their admission. For this sensitivity analysis and in contrast to the primary analysis, time from onset-to-arrival was significantly associated with death by 30 days (OR 0.99, 0.97 to 1.00; p=0.03) so was included in the multifactorial model. With all patients now included, admission during the implementation period was no longer significantly associated with a reduced odds of death by 30 days (OR 0·69, 0·42 to 1.06, p=0·09) but admission after implementation remained strongly significantly associated with a reduced odds of death by 30 days (OR 0·41, 0·24 to 0·63, p<0·0001). The quasi-experimental difference-in-difference analysis included 32,295 patients with ICH from 214 other hospitals in England and Wales. This demonstrated a 10·8 pp (95%CI -17·9 to -3·7; p = 0·003) absolute reduction in 30-day case fatality associated with the implementation of the care bundle (Figure 3).

Changes to improve DNT for anticoagulant reversal had been made prior to 1 June 2013.[13] No significant change in the median DNT was thus noted (Table 4) between the before implementation (132·0 min, IQR: 93·5 to 162·5 min) and implementation period (152·5 min, IQR: 87·0 to 210·2 min), but improvements were noted during the after implementation period (105·5 min, IQR: 75·5 to 200·5 min). During the implementation period (vs. before implementation), more eligible patients received intravenous anti-hypertensive drugs to lower acute BP (86% versus 55%, p<0·0001)

and for eligible patients receiving intravenous antihypertensive drugs, the median NTT markedly improved (43 minutes versus 383 minutes; p <0·0001). The median of each patient's mean SBP over 72 h was lower in the implementation (152.8 mmHg, IQR: 145.4 to 163.5 mmHg) and after implementation groups (152.2 mmHg, IQR: 145.6 to 162·3), compared to before implementation (166.7 mmHg, IQR: 158.3 to 174.4). No significant difference was observed before and after implementation in the variability of SBP over 72 h, as measured by the standard deviation of each patients SBP recordings. Supportive care improved in both the implementation and after implementation period, with more patients being admitted to HDU (18/347 [5·2%] before implementation; 32/266 [12·0%] implementation; 25/243 [10·4%] after implementation) and less use of DNR orders within 24 h (96/351 [27·4%] before implementation; 47/266 [17·7%] implementation; 38/243 [15.8%] after implementation). During the after implementation period, but not the implementation period, more eligible patients underwent neurosurgery (16/40 [40·0%] before implementation; 20/54 [37·0%] implementation; 19/28 [67·9%] after implementation).

Model-based mediation analysis gives an understanding of how the components of the care bundle individually contributed to the overall effect. The total effect is decomposed into two components: the natural direct effect (NDE) and the natural indirect effect (NIE). A significant NIE suggests that the process mediated the overall effect. The mediation analysis (Table 5) demonstrated that the observed reduction in DNR orders within 24 h mediated 52·8% of the association between care bundle implementation and lower 30-day case fatality and increased admission to HDU mediated 11·1%. As DNT for anticoagulation reversal was not significantly lower after implementation it could not have been a mediating factor. Although all improved after bundle implementation, time from onset to surgery, intensive blood pressure lowering, NTT and change in SBP from arrival to 4 h after arrival were not significant mediating factors. As a sensitivity analysis, we repeated the mediation analysis for all patients admitted during the study period, including patients where a decision was made to restrict care to palliation only within one hour of arrival in hospital and those

who were not under the care of stroke or neurosurgery during their admission. Again, only access to HDU and DNR within 24 h were significant mediators, mediating 12.5% and 56.0% of the overall association, respectively.

Discussion:

Within the setting of an active quality improvement program to improve acute care for patients with ICH, implementation of the ABC bundle was associated with improved delivery of intensive blood pressure lowering, better access to neurosurgery, improved supportive care, and a relative reduction in 30-day case fatality of over a third, which was not accounted for by case-mix or secular national trends. These improvements in care and survival were sustained for the year following the ABC-ICH project. This study supports the hypothesis that consistent and effective delivery of evidence-based, guideline-recommended care to acute ICH patients may lead to a marked improvement in survival, suggesting that existing therapeutic nihilism[3] may no longer be justified. We have shown that a comprehensive implementation strategy comprising executive and senior leader support, multidisciplinary working, continuous audit and feedback, PDSA cycles, education and simulation training was effective in introducing, delivering and sustaining the ABC bundle in the setting of a Comprehensive Stroke Centre.

Prior to the ABC-ICH project, we improved DNT for anticoagulant reversal[13] and this did not improve further during the implementation period. Although this means it cannot have contributed significantly to the observed reduction in case fatality, there is both observational and clinical trial data to suggest that prompt reversal of anticoagulation improves survival,[4–6] making it an important component of the ABC care bundle. Marked improvements were made in the delivery of intensive BP lowering and our finding that this did not mediate improved survival is consistent with the findings of the INTERACT2 trial, in which the intervention reduced disability and improved quality of life but did not improve survival. Our care pathway was based on existing evidence[8,16] and guidleines[10,11] and was associated with a significant

increase in the percentage of eligible patients undergoing acute neurosurgery. Although neurosurgery was not a significant mediator of the associated reduction in case fatality, this may be attributable to low statistical power as only 6.4% of patients underwent surgery overall. While not explicitly part of the ABC care bundle, we found that more patients were admitted to HDU and less had a DNR order within 24 h or arrival once the care bundle was implemented. This suggests that a cultural shift towards a less nihilistic approach to ICH care occurred, perhaps as an indirect effect of ABC care bundle implementation. Our mediation analysis suggests that over half of the association between improved survival and implementation of the care bundle is attributable to this reduction in early DNR orders, with a smaller percentage attributable to HDU admission. In support of this finding, a previous prospective, observational, cohort study demonstrated that up to a third of ICH patients with a GCS ≤ 12 make a good recovery if DNR orders were limited, contrary to predictions based on severity grading scales, such as the ICH score.[17,18]

Our study has some limitations. Firstly, the study design prevents us from making firm conclusions regarding a causal relationship between the ABC care bundle and lower case fatality, even though the use of the quasi-experimental difference-in-difference methodology provides support for a causal effect. Further testing in a cluster-randomized trial will be required to definitively test our study hypotheses. Secondly, we did not have sufficient resources to measure longer-term disability (for example, mRS score at 6 months). We do not therefore know what impact the bundle had on the disability profile in survivors. Our hypothesis is that the care bundle will lead to a shift towards improved outcome across the entire range of mRS, a composite outcome of death and disability. For example, it may be that patients who would have died from their ICH will survive with severe disability, but also those that would have survived with severe disability without the bundle will survive with mild or moderate disability instead. The evidence underpinning the care processes changed by the care bundle supports this. The INTERACT2 trial demonstrated a reduction in disability across the entire range of the mRS.[7] Rapidly reversing

anticoagulation will prevent small hematomas expanding,[5,6] thus preventing mild-moderate strokes deteriorating to severe strokes or death. Individual patient data meta-analysis of trials of hematoma evacuation has shown a reduction in 'unfavorable outcome' (defined as death plus the vegetative state or severe disability) with surgery in the patients we are targeting with our care pathway.[8] A multicenter prospective observational study has tested a policy of avoiding DNR orders in first 5 days of care in a subgroup of patients with severe ICH (defined as Glasgow Coma Scale [GCS] score ≤ 12).[17] 30-day case fatality was predicted to be 50% but was observed to be 20·2%. At 90 days, 27·1% had died, 21·5% had severe disability, 29·9% had moderately severe disability, but a better recovery (mRS 0-3) was achieved by 29·9%. In other words, in this group of severe ICH that most clinicians would consider to have a poor prognosis, nearly a third made a good recovery. Thirdly, changes were made to the centralized stroke pathway in Greater Manchester in March 2015 that might be expected to impact on ICH care and outcomes. The time window from symptom onset for diverting patients to one of the three hyperacute stroke units (HASUs) changed from 4 h to 48 h and once admitted patients remained at the HASU for 72 h, compared to 24 h before the reorganization. We have shown that the ICH case mix did not change during the study period (Table 2), suggesting that the ABC-ICH project and not the pathway reorganization accounted for the changes observed at Salford.

In summary, ICH is a major cause of death and disability worldwide and we present evidence suggesting that simple strategies to consistently and effectively deliver our ABC care bundle might lead to an improvement in survival. Further evaluation of the ABC care bundle in a cluster randomized trial is needed to establish clinical and cost effectiveness, including a measure of later disability as the primary outcome. If proven to be effective in prospective trials, implementation of the ABC care bundle could significantly reduce the substantial morbidity and mortality associated with this otherwise severe subtype of stroke.

Author contributions: APJ, HP, KP, EB, LC, BB, RE and MM contributed to the conception and design of the study; APJ, EB, MM, KP, LC, JR, SL, CSP, BB and RE contributed to the acquisition and analysis of data; APJ, CSP, KP, BB, HP contributed to drafting the text and preparing the figures.

Potential conflicts of interest:

Nothing to report.

References:

1 van Asch CJ, Luitse MJ, Rinkel GJ, *et al.* Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. *The Lancet Neurology* 2010; **9**: 167–76.

2 Feigin VL, Krishnamurthi RV, Parmar P, *et al.* Update on the Global Burden of Ischemic and Hemorrhagic Stroke in 1990-2013: The GBD 2013 Study. *Neuroepidemiology* 2015; **45**: 161–76.

3 Parry-Jones AR, Paley L, Bray BD, *et al.* Care-limiting decisions in acute stroke and association with survival: analyses of UK national quality register data. *Int J Stroke* 2016; **11**: 321–31.

4   Parry-Jones AR, Di Napoli M, Goldstein JN, *et al.* Reversal strategies for vitamin K antagonists in acute intracerebral hemorrhage. *Ann Neurol* 2015; published online April 8. DOI:10.1002/ana.24416.

5   Kuramatsu JB, Gerner ST, Schellinger PD, *et al.* Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. *JAMA* 2015; **313**: 824–36.

6   Steiner T, Poli S, Griebe M, *et al.* Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. *Lancet Neurol* 2016; **15**: 566–73.

7   Anderson CS, Heeley E, Huang Y, *et al.* Rapid Blood-Pressure Lowering in Patients with Acute Intracerebral Hemorrhage. *N Engl J Med* 2013; published online May 29. DOI:10.1056/NEJMoa1214609.

8   Gregson BA, Broderick JP, Auer LM, *et al.* Individual Patient Data Subgroup Meta-Analysis of Surgery for Spontaneous Supratentorial Intracerebral Hemorrhage. *Stroke* 2012; **43**: 1496–504.

9   Mohamed S, Patel H, Aljohar F, *et al.* Does Surgery reduce mortality in patients with a cerebellar ICH? Observations from am international, multicentre, pooled dataset. In: European Stroke Organisation Conference: Abstracts. Gothenburg: European Stroke Journal, 2018: 3–204.

10   Hemphill JC, Greenberg SM, Anderson CS, *et al.* Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke* 2015; published online May 28. DOI:10.1161/STR.0000000000000069.

11   Intercollegiate Stroke Working Party. National clinical guideline for stroke. 2016.

12   Kothari RU, Brott T, Broderick JP, *et al.* The ABCs of Measuring Intracerebral Hemorrhage Volumes. *Stroke* 1996; **27**: 1304–5.

13   Parry-Jones A. Cutting delays in reversing anticoagulation after intracerebral haemorrhage: three key changes at a UK comprehensive stroke centre. *BMJ Qual Improv Report* 2015; **4**: u208763.w3521.

14   Imai K, Keele L, Tingley D. A general approach to causal mediation analysis. *Psychol Methods* 2010; **15**: 309–34.

15   Tingley D, Yamamoto T, Hirose K *et al.* mediation: R Package for Causal Mediation Analysis. *Journal of Statistical Software* 2014; **59**: 1–38.

16   Mendelow AD, Gregson BA, Rowan EN *et al.* Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral hematomas (STICH II): a randomised trial. *The Lancet* 2013; **382**: 397–408.

17   Morgenstern LB, Zahuranec DB, Sánchez BN, *et al.* Full medical support for intracerebral hemorrhage. *Neurology* 2015; **84**: 1739–44.

18   Hemphill JC 3rd, Bonovich DC, Besmertis L, *et al.* The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. *Stroke* 2001; **32**: 891–7.

Figure legends:

Figure 1: Summary of patients admitted before, during and after bundle implementation

Figure 2: Survival after acute ICH at Salford Royal Hospital: Kaplan-Meier curve showing survival for first 30 days after admission during the before implementation (solid line), implementation (dashed line) and after implementation (dotted line) periods. Survival was more likely in the implementation and after implementation periods (p<0·001; logrank test).

Figure 3: Difference-in-difference analysis: Salford Royal Hospital (circles) compared to the rest of England and Wales (crosses, n=32,295). Points signify 30-day case fatality for patients admitted during each 2-month period from 1 Jun 2013 to 31 May 2017. A regression line for each group (Salford Royal Hospital, solid line; rest of England and Wales, dashed line) before and after bundle implementation from 1 Jun 2015 was fitted.

Table 1: Baseline characteristics for all consecutive Salford Royal Hospital acute ICH patients: Columns represent time periods in relation to ABC care bundle implementation; before implementation (1 Jun 2013 to 31 May 2015), implementation (1 Jun 2015 to 31 May 2016), and after implementation (1 Jun 2016 to 31 May 2017). Patients palliated on admission and/or not admitted under stroke or neurosurgery are included. All data are presented as median and interquartile range, unless otherwise stated. Where data are missing, the number of complete cases is shown as the denominator or the number missing is indicated. GCS=Glasgow Coma Scale, ICH=intracerebral haemorrhage, IVH=intraventricular haemorrhage, mRS=modified Rankin Scale, SBP=systolic blood pressure.

Age	71·5 (57.1 – 81·2)	69·5 (55·2 – 80·0)	72.8 (61.0 – 81.1)	0·09
Premorbid mRS (0-2); n(%)	321 (79.7%)	243 (80.2%)	231 (86.5%)	0·06
Anticoagulant; n(%)	56 (13.9%)	43 (14.2%)	34 (12.7%)	0·87
Sex (female); n(%)	213 (52·9%)	147 (48·5%)	149 (55.8%)	0·21
GCS	14 (10-15)	14 (10-15)	14 (10-15)	0·82
Route of arrival; n(%)	Direct 315 (78.2%) Transfer 67 (16.6%) In-patient 8 (2.0%) Other 13 (3.2%)	Direct 194 (64.0%) Transfer 83 (27.4%) In-patient 8 (2.6%) Other 18 (5.9%)	Direct 167 (62.5%) Transfer 84 (31.5%) In-patient 3 (1.1%) Other 13 (4.9%)	P<0.0001
Palliated on admission; n(%)	40 (9·9%)	22 (7.3%)	13 (4·9%)	0·05
SBP on admission	169 (148-200)	166 (144-193)	163 (142-189)	0·06
Infratentorial; n(%)	51 (12·7%)	38 (12·5%)	33/265 (12.5%)	0·99
IVH; n(%)	157/402 (39.1%)	122 (40.3%)	95/265 (35.8%)	0·54
ICH volume (ml)	17·6 (5.9 – 51.1) 1 missing	16.6 (5·0 – 46·1)	19·5 (6·3 – 48·9) 2 missing	0·53

Table 2: Baseline characteristics for Salford Royal Hospital acute ICH patients admitted under Stroke Medicine or Neurosurgery and not palliated on admission: Columns represent time periods in relation to ABC care bundle implementation; before implementation (1 Jun 2013 to 31 May 2015), implementation (1 Jun 2015 to 31 May 2016), and after implementation (1 Jun 2016 to 31 May 2017). Patients palliated on admission and/or not admitted under stroke or neurosurgery were excluded. All data are presented as median and interquartile range, unless otherwise stated. All fields were complete for all patients. GCS=Glasgow Coma Scale, ICH=intracerebral hemorrhage, IVH=intraventricular hemorrhage, mRS=modified Rankin Scale, SBP=systolic blood pressure.

Age	69·8 (55·6 – 80·1)	68·5 (53·7 – 79·8)	71·2 (59·6 – 80·3)	0·11
Premorbid mRS (0-2); n(%)	286 (81·0%)	220 (82·7%)	212 (88·0%)	0·08
Anticoagulant; n(%)	47 (13·3%)	36 (13·5%)	29 (12·0%)	0·86
Sex (female); n(%)	186 (52·5%)	128 (48·1%)	127 (52·7%)	0·46
GCS	14 (11-15)	14 (11-15)	14 (11-15)	0·45
Route of arrival; n(%)	Direct 281 (79.6%) Transfer 65 (18.4%) In-patient 7 (2.0%)	Direct 177 (66.5%) Transfer 83 (31.2%) In-patient 6 (2.3%)	Direct 158 (65.6%) Transfer 81 (33.6%) In-patient 2 (0.8%)	P<0.0001
SBP on admission	168 (150 - 198)	165 (144 - 193)	162 (141 - 188)	0·09
Infratentorial hemorrhage; n(%)	37 (10·5%)	32 (12·0%)	28 (11·6%)	0·82
Intraventricular hemorrhage; n(%)	124 (35·1%)	98 (36·8%)	79 (32·8%)	0·63
ICH volume (ml)	14·0 (5·4 – 38·5)	15·3 (5·0 – 42·3)	18·4 (5·9 – 42·3)	0·41

Table 3: Factors associated with death by 30-days after admission with acute ICH at Salford Royal Hospital: Results of a multivariable logistic regression model testing the association between admission period (before implementation, implementation, after implementation) and death by 30-days, adjusting for key ICH prognostic indicators. Onset-to-arrival time and route of arrival (direct admission, transfer, inpatient stroke) were not significant so were excluded from the model. GCS=Glasgow Coma Scale, ICH=intracerebral hemorrhage, IVH=intraventricular hemorrhage, mRS=modified Rankin Scale.

Premorbid mRS (vs. 0)				
1	0·84	0·41	1·42	0·50
2	1·90	0·92	3·33	0·08
3	3·13	1·70	5·34	<0·0001
4	3·04	1·28	5·98	0·01
5	2·46	0·32	9·30	0·85
Age	1·06	1·04	1·08	<0·0001
GCS at arrival	0·82	0·77	0·87	<0·0001
Infratentorial (vs· supra)	2·05	1·10	3·43	0·02
IVH	2·03	1·35	3·00	<0·0001
ICH volume	1·02	1·02	1·03	<0·0001
Taking anticoagulants	1·74	1·05	2·80	0·04
Implementation period (vs. before implementation)	0·62	0·38	0·97	0·03
After implementation period (vs. before implementation)	0·40	0·24	0·61	<0·0001

Table 4: Process and care measures: Key process and care measures during each study period at Salford Royal Hospital. All data are presented as median and interquartile range, unless otherwise stated. Where data are missing, the number of complete cases is shown as the denominator. DNT=door to needle time, DNR=do-not-resuscitate, IQR=interquartile range, NTT-needle to target time, SBP=systolic blood pressure, SD=standard deviation.

DNT (min)	132·0 (93·5-162·5)	152·5 (87·0-210·2)	105·5 (75·5-200·5)	0·65
Intravenous antihypertensive (n, number eligible, % of eligible)	94/172 (54.7)	70/82 (85.4)	58/69 (84.1)	<0·0001
NTT (min)	383·0 (219·5-924·5)	43.0 (27.5-75·0)	50·0 (35·0-65·0)	<0·0001
Mean SBP 0-72 h (mmHg)	166.7 (158·3-174·4)	152·8 (145·4-163·5)	152.1 (145·6-162·3)	<0·01
SD of SBP 0-72 h (mmHg)	25.7 (19.3-32.0)	25·0 (19.4-31.7)	25.0 (19·5-29·7)	0·88
Neurosurgery; (n, number eligible, % of eligible)	16/40 (40·0)	20/54 (37·0)	19/28 (67·9)	0·02
High Dependency Unit; n (%)	19 (5·4)	32 (12·0)	25 (10·4)	<0·01
Intensive Care Unit; n (%)	50 (14·2)	47 (17·7)	49 (20·3)	0·14
DNR < 24 h; n (%)	96 (27·2)	47 (17·7)	38 (15·8)	<0·001

Table 5: Mediation analysis: Results of analysis to determine factors mediating the association between bundle implementation and 30-day survival. Door-to-anticoagulant reversal time, intensive BP lowering, door-to-blood pressure target time, change in SBP from 0 to 4 h, admission to intensive care unit and neurosurgery were not significant mediators CI=confidence interval, DNR=Do-not-resuscitate order, HDU=High Dependency Unit, NDE=natural direct effect, NIE=natural indirect effect, SBP=systolic blood pressure.

|	Estimate (p-value)	95% CI	Estimate (p-value)	95% CI	Estimate (p-value)	95% CI	
Access to HDU	-0·0594 (0·01)	(-0·1104, -0·01)	-0·0070 (0·03)	(-0·0164, 0·00)	-0·0524 (0·04)	(-0·1032, 0·00)	11·1%
DNR within 24 h	-0·0607 (0·02)	(-0·1109, -0·01)	-0·0324 (<0·01)	(-0·0581, -0·01)	-0·0284 (0·23)	(-0·0770, 0·02)	52·8%

Figure1: Summary of patients admitted before, during and after bundle implementation

Figure 2: Survival after acute ICH at Salford Royal Hospital

Figure 3: Difference-in-difference analysis